| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8349871 | Pharmacology Biochemistry and Behavior | 2018 | 32 Pages |
Abstract
Our research supports the hypothesis that changes in the levels of GABA and/or 5-HT1A receptors may contribute to the schizophrenia-like phenotype, and GABAergic and serotonergic agents may be good candidates for treating negative symptoms of schizophrenia.
Keywords
SDSAntipsychotic effect5-HIAADOPACN-methyl-d-aspartateNMDAqRT-PCRGADPCPGAPDHRT-PCR5-Hydroxyindoleacetic acidSchizophreniaHomovanilic acidsodium dodecyl sulphatenegative symptomsPhencyclidineAnimal modelsReal time polymerase chain reactionWestern blottingHVAhigh performance liquid chromatographyHPLCGABABGlutamate decarboxylaseglyceraldehyde 3-phosphate dehydrogenase
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Monika Woźniak, Paulina CieÅlik, Marcin Marciniak, Tomasz Lenda, Andrzej Pilc, Joanna M. Wieronska,